[
  {
    "ts": null,
    "headline": "CytomX Stock Rises 31% in a Month: Here's What You Should Know",
    "summary": "CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.",
    "url": "https://finnhub.io/api/news?id=c9f2832a6ce58830b0db1e61a3f0309cacc0c0d92b6c5b9e4e66351971909b84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768832220,
      "headline": "CytomX Stock Rises 31% in a Month: Here's What You Should Know",
      "id": 138177976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.",
      "url": "https://finnhub.io/api/news?id=c9f2832a6ce58830b0db1e61a3f0309cacc0c0d92b6c5b9e4e66351971909b84"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Valuation Check After Raised 2025 Outlook And Cost Cuts At JPMorgan Conference",
    "summary": "Moderna (MRNA) has jumped back into focus after its JPMorgan Healthcare Conference update, where management lifted the 2025 revenue forecast to about US$1.9b, cut operating expense guidance by US$200m, and pointed to a stronger cash position. See our latest analysis for Moderna. The 21.95% 7 day share price return and 53.56% 90 day share price return suggest momentum has picked up recently. However, the 22.81% 1 year total shareholder return contrasts with weak 3 and 5 year total shareholder...",
    "url": "https://finnhub.io/api/news?id=a7a6ef6ebea69d248bd5352dc6e2278c8f36467a2b15e606ca9f06290ae6cd2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768799249,
      "headline": "Moderna (MRNA) Valuation Check After Raised 2025 Outlook And Cost Cuts At JPMorgan Conference",
      "id": 138174562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) has jumped back into focus after its JPMorgan Healthcare Conference update, where management lifted the 2025 revenue forecast to about US$1.9b, cut operating expense guidance by US$200m, and pointed to a stronger cash position. See our latest analysis for Moderna. The 21.95% 7 day share price return and 53.56% 90 day share price return suggest momentum has picked up recently. However, the 22.81% 1 year total shareholder return contrasts with weak 3 and 5 year total shareholder...",
      "url": "https://finnhub.io/api/news?id=a7a6ef6ebea69d248bd5352dc6e2278c8f36467a2b15e606ca9f06290ae6cd2d"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks Walking a Fine Line",
    "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 23.7% gain over the past six months, beating the S&P 500 by 13.6 percentage points.",
    "url": "https://finnhub.io/api/news?id=646602d8b51f4849bf6e4b5d0f1342a562741eb6832d44e7fb42de96bc974def",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768797310,
      "headline": "3 Healthcare Stocks Walking a Fine Line",
      "id": 138179175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 23.7% gain over the past six months, beating the S&P 500 by 13.6 percentage points.",
      "url": "https://finnhub.io/api/news?id=646602d8b51f4849bf6e4b5d0f1342a562741eb6832d44e7fb42de96bc974def"
    }
  }
]